{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:56:34Z","timestamp":1772045794383,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>One of the main and effective therapy choices for patients with metastatic castration-resistant prostate cancer (mCRPC) is cabazitaxel (CBZ). Cystitis and hematuria are among the most significant non-hematological adverse events associated with CBZ treatment. But because the prevalence of CBZ-induced ureteritis has not been thoroughly studied, this case series investigation was carried out to emphasize the condition\u2019s clinical relevance and potential treatment alternatives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>Between June 2014 and May 2024, 354 patients diagnosed with mCRPC were treated with CBZ at the Department of Oncology, Vejle Hospital. A total of 36 patients (10%) exhibited ureteritis-like symptoms, presenting with discomfort in the pelvis, lower abdomen, or flanks, with or without hematuria. Radiological evidence of ureter changes was present in 29 out of 36 individuals (80%), along with hydronephrosis\/hydroureter in some patients. Prior to therapy with CBZ, radiation to the pelvis or lower abdomen was documented in 7 out of 36 patients (19%). Various analgesics and dosage modifications were considered for the therapy of CBZ-induced ureteritis, with treatment discontinuation yielding the most favorable results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The onset of ureteritis during CBZ treatment is an underrated side effect in clinical practice. Hematuria and hydronephrosis\/hydroureter are the most associated complications. Both analgesics and dosage reduction should be contemplated for management, while therapy cessation may be requisite in certain individuals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00872-2","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T21:38:26Z","timestamp":1744234706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014\u20132024"],"prefix":"10.1186","volume":"25","author":[{"given":"Ahmed H.","family":"Zedan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper S.","family":"Gade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten Egbert Arnold","family":"Zieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja Schmidt","family":"Vejlgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip Lund Hjorth","family":"Fredensborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"872_CR1","doi-asserted-by":"crossref","unstructured":"FDA approves new combined treatment for advanced prostate cancer. Vol. 129, Cancer. 2010 [cited 2024 Sep 8]. pp. 3841\u20132. Available from: https:\/\/web.archive.org\/web\/20100619162218\/http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm216143.htm","DOI":"10.1002\/cncr.35122"},{"key":"872_CR2","unstructured":"Jevtana | European Medicines Agency (EMA). [cited 2024 Sep 8]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jevtana"},{"key":"872_CR3","doi-asserted-by":"crossref","unstructured":"Vrignaud P, S\u00e9miond D, Lejeune P, Bouchard H, Calvet L, Combeau C et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013 Jun 1 [cited 2024 Sep 8];19(11):2973\u201383. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23589177\/","DOI":"10.1158\/1078-0432.CCR-12-3146"},{"key":"872_CR4","doi-asserted-by":"crossref","unstructured":"De Bono JS, Oudard S, Ozguroglu M, Hansen S, MacHiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010 Oct 2 [cited 2024 Oct 7];376(9747):1147\u201354. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20888992\/","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"872_CR5","doi-asserted-by":"crossref","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, Daugaard G, Saad F, Hansen S et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial - FIRSTANA. J Clin Oncol. 2017 Oct 1 [cited 2024 Oct 7];35(28):3189\u201397. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28753384\/","DOI":"10.1200\/JCO.2016.72.1068"},{"key":"872_CR6","unstructured":"Lescay HA, Jiang J, Leslie SW, Tuma F, Anatomy. Abdomen and Pelvis Ureter. StatPearls. 2024 May 5 [cited 2025 Feb 14]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532980\/"},{"key":"872_CR7","doi-asserted-by":"publisher","unstructured":"Bechtold RB, Bechtold RB, Chen MVM, Dyer RB, Zagoria RJ. CT of the ureteral wall. Am Roentgen Ray Soc. 1998 [cited 2025 Feb 14];1283. Available from: https:\/\/doi.org\/10.2214\/ajr.170.5.9574602","DOI":"10.2214\/ajr.170.5.9574602"},{"key":"872_CR8","doi-asserted-by":"crossref","unstructured":"Cook FV, Farrar WE, Kreutner A. Hemorrhagic cystitis and ureteritis, and interstitial nephritis associated with administration of penicillin G. J Urol. 1979 [cited 2025 Feb 14];122(1):110\u20131. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37350\/","DOI":"10.1016\/S0022-5347(17)56278-3"},{"key":"872_CR9","doi-asserted-by":"crossref","unstructured":"Tu L, Ye Y, Tang X, Liang Z, You Q, Zhou J et al. Case Report: A Case of Sintilimab-Induced Cystitis\/Ureteritis and Review of Sintilimab-Related Adverse Events. Front Oncol. 2021 Dec 23 [cited 2025 Feb 14];11. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35004277\/","DOI":"10.3389\/fonc.2021.757069"},{"key":"872_CR10","doi-asserted-by":"crossref","unstructured":"Li J, Yu YF, Qi XW, Du Y, Li CQ. Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review. Front Immunol. 2023 Jan 6 [cited 2025 Feb 14];13:1051577. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9853439\/","DOI":"10.3389\/fimmu.2022.1051577"},{"issue":"2","key":"872_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/gyno.1999.5680","volume":"76","author":"TM Wong","year":"2000","unstructured":"Wong TM, Yeo W, Chan LW, Mok TSK. Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. Gynecol Oncol. 2000;76(2):223\u20135.","journal-title":"Gynecol Oncol"},{"key":"872_CR12","doi-asserted-by":"publisher","unstructured":"Kosaka T, Oya M. Hemorrhagic cystitis in a patient without a past history of radiation therapy who was treated with cabazitaxel for CRPC. Ann Oncol. 2015;26(11):2355\u20136. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdv362","DOI":"10.1093\/annonc\/mdv362"},{"issue":"3","key":"872_CR13","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/j.clgc.2016.12.003","volume":"15","author":"MA Bilen","year":"2017","unstructured":"Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, et al. Safety of Same-day pegfilgrastim administration in metastatic Castration-resistant prostate cancer treated with Cabazitaxel with or without carboplatin. Clin Genitourin Cancer. 2017;15(3):e429\u201335.","journal-title":"Clin Genitourin Cancer"},{"key":"872_CR14","unstructured":"EMA. Jevtana cabazitaxel. 2012 [cited 2024 Sep 8]. Available from: www.ema.europa.eu\/contact"},{"issue":"1","key":"872_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-017-0119-3","volume":"17","author":"GN Malalagama","year":"2017","unstructured":"Malalagama GN, Chryssidis S, Parnis FX. CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: A case series. Cancer Imaging. 2017;17(1):1\u20135.","journal-title":"Cancer Imaging"},{"key":"872_CR16","doi-asserted-by":"crossref","unstructured":"Burris HA, Hurtig J. Radiation Recall with Anticancer Agents. Oncologist. 2010 [cited 2024 Sep 8];15(11):1227\u201337. Available from: http:\/\/www.TheOncologist.com.","DOI":"10.1634\/theoncologist.2009-0090"},{"key":"872_CR17","doi-asserted-by":"crossref","unstructured":"D\u2019ANGIO GJ, MADDOCK FARBERS. CL. Potentiation of x-ray effects by actinomycin D. Radiology. 1959 [cited 2025 Feb 14];73:175\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/13813586\/","DOI":"10.1148\/73.2.175"},{"issue":"7","key":"872_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ctrv.2005.07.008","volume":"31","author":"D Azria","year":"2005","unstructured":"Azria D, Magn\u00e9 N, Zouhair A, Castadot P, Culine S, Ychou M, et al. Radiation recall: A well recognized but neglected phenomenon. Cancer Treat Rev. 2005;31(7):555\u201370.","journal-title":"Cancer Treat Rev"},{"key":"872_CR19","doi-asserted-by":"publisher","unstructured":"McKay MJ, Dumbrava M, McKay JN, McKay TA. Cutaneous chemotherapy-induced radiation recall reaction. Clin Case Reports. 2021 May 1 [cited 2025 Feb 14];9(5). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ccr3.4306","DOI":"10.1002\/ccr3.4306"},{"key":"872_CR20","doi-asserted-by":"crossref","unstructured":"Visy A, Bachelot T, Racadot S. Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus. Cancer Radiother. 2019 Sep 1 [cited 2025 Feb 14];23(5):423\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31176579\/","DOI":"10.1016\/j.canrad.2019.01.005"},{"issue":"6","key":"872_CR21","first-page":"744","volume":"9","author":"MW Saif","year":"2008","unstructured":"Saif MW, Ramos J, Knisely J. Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. J Pancreas. 2008;9(6):744\u20137.","journal-title":"J Pancreas"},{"key":"872_CR22","doi-asserted-by":"crossref","unstructured":"Gabel C, Eifel PJ, Tornos C, Burke TW. Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynecol Oncol. 1995 [cited 2025 Feb 14];57(2):266\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7729748\/","DOI":"10.1006\/gyno.1995.1139"},{"issue":"4","key":"872_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.ijrobp.2006.05.073","volume":"66","author":"M Mizumoto","year":"2006","unstructured":"Mizumoto M, Harada H, Asakura H, Zenda S, Fuji H, Murayama S, et al. Frequency and characteristics of docetaxel-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys. 2006;66(4):1187\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"872_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00001813-200308000-00011","volume":"14","author":"A Jimeno","year":"2003","unstructured":"Jimeno A, Ciruelos EM, Castellano D, Caballero B, Rodriguez-Peralto JL, Cort\u00e9s-Funes H. Radiation recall dermatitis induced by pegylated liposomal doxorubicin. Anticancer Drugs. 2003;14(7):575\u20136.","journal-title":"Anticancer Drugs"},{"key":"872_CR25","doi-asserted-by":"crossref","unstructured":"Jeter MD, J\u00e4nne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 1 [cited 2025 Feb 14];53(2):394\u2013400. Available from: http:\/\/www.redjournal.org\/article\/S0360301602027736\/fulltext","DOI":"10.1016\/S0360-3016(02)02773-6"},{"key":"872_CR26","doi-asserted-by":"crossref","unstructured":"Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001 Jun 1 [cited 2025 Feb 14];59(3):237\u201345. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11369064\/","DOI":"10.1016\/S0167-8140(01)00328-0"},{"key":"872_CR27","doi-asserted-by":"crossref","unstructured":"Winnie Y, Johnson PJ. Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management. Am J Clin Dermatol. 2000 [cited 2025 Feb 14];1(2):113\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11702310\/","DOI":"10.2165\/00128071-200001020-00006"},{"issue":"28","key":"872_CR28","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard AC, Kim CS, G\u00e9czi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of Cabazitaxel (20\u00a0mg\/m2) and the currently approved dose (25\u00a0mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer - PROSELICA. J Clin Oncol. 2017;35(28):3198\u2013206.","journal-title":"J Clin Oncol"},{"issue":"26","key":"872_CR29","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506\u201318.","journal-title":"N Engl J Med"},{"key":"872_CR30","doi-asserted-by":"crossref","unstructured":"Obayashi A, Hamada-Nishimoto M, Fujimoto Y, Yoshimoto Y, Takahara S. Non-bacterial Cystitis With Increased Expression of Programmed Cell Death Ligand 1 in the Urothelium: An Unusual Immune-Related Adverse Event After Atezolizumab Administration for Metastatic Breast Cancer. Cureus. 2022 May 30 [cited 2025 Feb 17];14(5). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35800819\/","DOI":"10.7759\/cureus.25486"},{"key":"872_CR31","doi-asserted-by":"publisher","unstructured":"Stillwell TJ, Benson RC, Cyclophosphamide-Induced Hemorrhagic Cystitis A. Review of 100 Patients. [cited 2025 Feb 17]; Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/1097-0142","DOI":"10.1002\/1097-0142"},{"key":"872_CR32","doi-asserted-by":"publisher","unstructured":"Grellety T, Hou\u00e9d\u00e9 N, Hoepffner JL, Rivi\u00e8re J, M\u00e9rino C, Lieutenant V et al. Hemorrhagic cystitis in patients treated with cabazitaxel: A radiation recall syndrome? Ann Oncol. 2014;25(6):1248\u20139. Available from: https:\/\/doi.org\/10.1093\/annonc\/mdu132","DOI":"10.1093\/annonc\/mdu132"},{"issue":"12","key":"872_CR33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","volume":"121","author":"M Rouyer","year":"2019","unstructured":"Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, et al. Overall and progression-free survival with Cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br J Cancer. 2019;121(12):1001\u20138.","journal-title":"Br J Cancer"},{"key":"872_CR34","doi-asserted-by":"crossref","unstructured":"Crocetto F, Balsamo R, Amicuzi U, De Luca L, Falcone A, Mirto BF et al. Novel Key Ingredients in Urinary Tract Health-The Role of D-mannose, Chondroitin Sulphate, Hyaluronic Acid, and N-acetylcysteine in Urinary Tract Infections (Uroial PLUS\u00ae). Nutrients. 2023 Aug 1 [cited 2025 Feb 16];15(16). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37630763\/","DOI":"10.3390\/nu15163573"},{"key":"872_CR35","doi-asserted-by":"crossref","unstructured":"Janssen DAW, Van Wijk XMR, Jansen KCFJ, Van Kuppevelt TH, Heesakkers JPFA, Schalken JA. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013 Jan [cited 2025 Feb 16];189(1):336\u201342. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23174248\/","DOI":"10.1016\/j.juro.2012.09.022"},{"key":"872_CR36","doi-asserted-by":"crossref","unstructured":"Stellavato A, Pirozzi AVA, Diana P, Reale S, Vassallo V, Fusco A et al. Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation. PLoS One. 2019 Jun 1 [cited 2025 Feb 16];14(6):e0218475. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0218475","DOI":"10.1371\/journal.pone.0218475"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00872-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T21:38:30Z","timestamp":1744234710000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00872-2","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Regional Data Agency in Southern Denmark (jr. nr. 24\/38556).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}